Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix.
The effect of the progesterone antagonist mifepristone on the cervix was investigated in two randomised double-blind placebo-controlled trials, the first in 30 women undergoing first trimester surgical termination of pregnancy and the second in 30 non-pregnant premenopausal women. 600 mg mifepristone, given orally 48 h before surgery, increased the mean preoperative cervical dilatation in both pregnant and non-pregnant treatment groups and also reduced the force required to dilate the pregnant and non-pregnant cervix.
Gupta
J K
JK
University Department of Obstetrics and Gynaecology, St James's University Hospital, Leeds, UK.
Johnson
N
N
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects* / Q000502:physiology; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D015735:Mifepristone / Q000008:administration & dosage / Q000494:pharmacology*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic
D015735:Mifepristone